Literature DB >> 18490502

Evaluation of antibiotic therapy for eradication of "Candidatus Helicobacter heilmannii".

Hidenori Matsui1, Chihiro Aikawa, Yukie Sekiya, Shinichi Takahashi, Somay Yamagata Murayama, Masahiko Nakamura.   

Abstract

Triple-agent therapy with lansoprazole (15 mg/kg)-clarithromycin (50 mg/kg)-amoxicillin (50 mg/kg) twice daily for 7 days fully cleared "Candidatus Helicobacter heilmannii" from infected mouse stomachs. Moreover, gastric mucosa-associated lymphoid tissue lymphoma-like lesions in the stomach nearly disappeared in the treated mice 4 months after the therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18490502      PMCID： PMC2493118          DOI： 10.1128/AAC.01662-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  "Candidatus Helicobacter heilmannii" from a cynomolgus monkey induces gastric mucosa-associated lymphoid tissue lymphomas in C57BL/6 mice.

Authors:  Masahiko Nakamura; Somay Yamagata Murayama; Hiroshi Serizawa; Yukie Sekiya; Masahiro Eguchi; Shinichi Takahashi; Kaori Nishikawa; Tetsufumi Takahashi; Tsukasa Matsumoto; Haruki Yamada; Toshifumi Hibi; Kanji Tsuchimoto; Hidenori Matsui
Journal:  Infect Immun       Date:  2006-12-28       Impact factor: 3.441

2.  Evaluation of antibiotic treatment against "Candidatus Helicobacter suis" in a mouse model.

Authors:  A Hellemans; A Decostere; F Haesebrouck; R Ducatelle
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Gastric mucosal changes induced by long term infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication.

Authors:  Y Keto; M Ebata; S Okabe
Journal:  J Physiol Paris       Date:  2001 Jan-Dec

4.  New spiral bacterium in gastric mucosa.

Authors:  C A McNulty; J C Dent; A Curry; J S Uff; G A Ford; M W Gear; S P Wilkinson
Journal:  J Clin Pathol       Date:  1989-06       Impact factor: 3.411

Review 5.  The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases.

Authors:  J G Fox
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection.

Authors:  A Morgner; N Lehn; L P Andersen; C Thiede; M Bennedsen; K Trebesius; B Neubauer; A Neubauer; M Stolte; E Bayerdörffer
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

Review 7.  Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases.

Authors:  J V Solnick; D B Schauer
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

8.  Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.

Authors:  Yoko Okiyama; Kenji Matsuzawa; Eiko Hidaka; Kenji Sano; Taiji Akamatsu; Hiroyoshi Ota
Journal:  Pathol Int       Date:  2005-07       Impact factor: 2.534

9.  [Low-grade gastric MALT lymphoma and helicobacter heilmannii (Gastrospirillum hominis].

Authors:  C Regimbeau; D Karsenti; V Durand; L D'Alteroche; C Copie-Bergman; E H Metman; M C Machet
Journal:  Gastroenterol Clin Biol       Date:  1998 Aug-Sep
  9 in total
  1 in total

1.  New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib.

Authors:  Masahiko Nakamura; Tetsufumi Takahashi; Hidenori Matsui; Shinichi Takahashi; Somay Y Murayama; Hidekazu Suzuki; Kanji Tsuchimoto
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.